The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia
Not Applicable
- Conditions
- Type2 diabetes mellitus patients with dyslipidemia
- Registration Number
- JPRN-UMIN000013682
- Lead Sponsor
- Internal Medicine, Teikyo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who accord the contraindication of anagliptin. 2.Patients whose HbA1c over 8.0% before entry. 3.Patients who suffered coronary heart disease in past. 4.Patients whose renal function is declined (Ccr below the 30) or ongoing dialysis. 5.Individuals who are ineligible in the opinion of the physician in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of sitosterol, campesterol and lathosterol
- Secondary Outcome Measures
Name Time Method Change of serum lipids and apolipoproteins